M&A / Deals GSK ends dementia alliance with Alector after setbacks PharmaphorumGSK's alliance with Alector to develop two drug candidates for dementia has been terminated in the wake of disappointing clinical trial results.NeuroscienceRead full story pharminent July 9, 2026 (Last updated: July 10, 2026) Pharmaphorum GSK’s alliance with Alector to develop two drug candidates for dementia has been terminated in the wake of disappointing clinical trial results. Neuroscience Read full story Post navigation Previous: FDA freezes CRL trove as ‘radical transparency’ push hits speedbumpNext: AstraZeneca, Ionis drug fails big heart disease study in major setback Related Stories M&A / Deals Exegenesis Bio and Modalis sign research deal for Duchenne therapy pharminent September 11, 2026 M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026